Glaucoma Therapeutics Pipeline Analysis, 2017 – Collaboration and Other Developments

Glaucoma Therapeutics Pipeline Analysis

Glaucoma is a collection of diseases that injure the optic nerve of the eyes and can eventually lead to loss of vision or complete blindness. People over the age of 60 years, especially Mexican Americans and African Americans and people with a family history of glaucoma are at greater risk of developing glaucoma at some point of time in their lives. It has also been observed that people with blood pressure and heart related problems are more likely to be affected by the condition. As per the estimates of the American Academy of Ophthalmology primary open-angle glaucoma, the most common type of glaucoma, affects as many as 2.2 million people in the U.S. This figure is projected to reach 3.3 million by 2020 as the prevalence of ageing population in the U.S. is increasing. Visual acuity test, dilated eye exam, tonometry and pachymetry are some of the tests used to diagnose the disease. Treatment of the disease include medicines, laser trabeculoplasty and surgical interventions.

Explore Report at: https://www.psmarketresearch.com/market-analysis/glaucoma-therapeutics-pipeline-analysis

Some of the main growth drivers of the pipeline of therapeutics for glaucoma include increasing geriatric population and expenditure on healthcare. New regulations that have increased the medical coverage of glaucoma drugs and increasing incidence of high blood pressure among general population are also expected to contribute to the growth in the pipeline of the disease. Innovations in the drug therapies for glaucoma is another key factor driving the growth of pipeline glaucoma therapeutics.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/glaucoma-therapeutics-pipeline-analysis/toc-sample

Some of the major players involved in the development of drug candidates for the treatment glaucoma include Allysta Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Adgero Biopharmaceuticals Inc., SENJU Pharmaceutical Co. Ltd., Mimetogen Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Inotek Pharmaceuticals Corporation, Ocular Therapeutix, Inc., Quark Pharmaceuticals, Inc., Lee’s Pharmaceutical Holdings Ltd., Allergan plc, Laboratoires THEA S.A.S, Gene Signal International SA, Zentiva N.V.

Alopecia Therapeutics Pipeline Analysis, 2017 – Collaboration and Other Developments

Alopecia Therapeutics Pipeline Analysis

Alopecia is a skin disease characterised by loss of hair on the scalp, face and less frequently on other parts of the body. According to the National Alopecia Areata Foundation, approximately 6.8 million people in the U.S. and about 147 million people globally are affected by the disease  and approximately 2.1% people have a lifetime risk of developing the disease. There are many types of alopecia of which male-pattern baldness is the most commonly encountered type that affects around 50% of males by 50 years of age globally. Male-pattern baldness is a hereditary condition and generally runs in families. Alopecia areata is characterised by patches of baldness. Alopecia areata is caused due to an abnormality with the immune system; however, risk factors for alopecia areata include diabetes, hyperthyroidism or Down’s syndrome. Alopecia can also be caused due to the cancer treatment chemotherapy or immunotherapy and radiotherapy. Treatment of alopecia areata include steroid injections; however, creams, gels or ointments may also be used. Immunotherapy is also used in some cases.

Explore Report at: https://www.psmarketresearch.com/market-analysis/alopecia-therapeutics-pipeline-analysis

Significant growth is expected in the therapeutics pipeline for alopecia in the future mainly attributed to the rising prevalence of diabetes, genetic cause of the disease which means the disease will run in families, new advances in the gene therapy and other treatment options for the disease, rising demand for male grooming products, and rising awareness among general population about the disease.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/alopecia-therapeutics-pipeline-analysis/toc-sample

Some of the major players involved in the development of drugs for alopecia include Pfizer Inc., Allargan plc, GlaxoSmithKline plc, Leo Pharma A/S, Millendo Therapeutics, Inc., Dong-A ST Co., Ltd., Polichem S.A., Berg LLC, Teva Pharmaceuticals USA, Follicum AB, Legacy Healthcare SA, Neosil, Inc., TetraLogic Pharmaceuticals Corp., Concert Pharmaceuticals Inc., Incyte Corporation, HairDx, LLC, Samumed LLC., Intrepid Therapeutics, Inc.

Mucopolysaccharidosis Therapeutics Pipeline Analysis 2017 – Collaboration and Other Developments

Mucopolysaccharidosis (Morquio Syndrome), is a group of inherited disorder in which body becomes unable to breakdown the mucopolysaccharides. Accumulation of mucopolysaccharides in cells as well as connective tissues causes the malfunctioning of metabolic enzymes. This malfunctioning may lead to occurrence of variety of health problems.  Mucopolysaccharidosis is autosomal dominant in most cases involving X-linked pattern of inheritance. The signs and symptoms of the disease varies by the type of mucopolysaccharidosis. Some of the other complications of the disease include affected physical appearance and malfunction of organ’s system functioning and its cognitive development in most cases.

Explore Report at: https://www.psmarketresearch.com/market-analysis/mucopolysaccharidosis-morquio-syndrome-therapeutics-pipeline-analysis

The prevalence of mucopolysaccharidosis varies based on its types. According to the Orphanet, one person in a population of 100,000 is affected with mucopolysaccharidosis type I or Hurler syndrome. According to the Journal of Applied Genetics, a survey was conducted between 1970 to 2010, which found that the prevalence of mucopolysaccharidosis type III was 0.86 out of 100,000 live births. Additionally, the prevalence in Polish population was estimated to be 1.81 out of 100,000 individuals. The growth in the pipeline of mucopolysaccharidosis therapeutics is attributed to increasing technical advancements in molecular biology and genetics. Gene therapies, cell therapies, immunotherapies and microRNA are the first line of treatment of mucopolysaccharidosis. The funding from rare disease organizations is also one of the factors, which is expected to increase the collaboration between companies, associations and institutes for the development of therapies for the treatment of mucopolysaccharidosis.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/mucopolysaccharidosis-morquio-syndrome-therapeutics-pipeline-analysis/toc-sample

In May 2017, the gene therapy, SB-913 from Sangamo Therapeutics Inc., was granted a rare pediatric disease designation by USFDA. In January 2017, another gene therapy from Sangamo Therapeutics Inc., SB-318, was designated as orphan drug by the USFDA.

Some of the companies having a pipeline of Mucopolysaccharidosis therapeutics include, Ultragenyx Pharmaceutical Inc., Shire plc, BioMarin Pharmaceutical Inc., ArmaGen Inc., Genzyme Inc., JCR Pharmaceuticals Co., Ltd., Green Cross Corporation, Alexion Pharmaceuticals Inc., Concert Pharmaceuticals Inc.

Lennox-Gastaut Syndrome Therapeutics Pipeline Analysis 2017

Lennox-Gastaut Syndrome Therapeutics Pipeline

Lennox-Gastaut Syndrome is a rare form of epilepsy that occurs in childhood and is characterized by seizures and intellectual disability. Adverse conditions such as injury to brain and its malformation, lack of oxygen to the new-born infants, infections of central nervous system and inherited metabolic or degenerative disorders are responsible for occurrence of Lennox-Gastaut Syndrome. Anti-epileptic medications are the main treatment option for Lennox-Gastaut Syndrome. The medication is often complicated in case of paediatric disorders as there is risk in development of new-born, due to which various research organizations are focussing on development of therapeutics of Lennox-Gastaut Syndrome.

Explore Report at: https://www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis

In August 2017, INSYS Therapeutics Inc. started a Phase III study of an oral solution of cannabidiol, to assess its safety and efficacy as an adjunctive therapy for treatment in subjects with uncontrolled Lennox-Gastaut Syndrome. The trial is expected to be completed in June 2018. In December 2016, Eisai Inc. conducted a Phase III study on its drug candidate, perampanel, for reducing the drop seizures in patients with uncontrolled seizures and Lennox-Gastaut Syndrome. The trial is expected to be completed in February 2020. In January 2016, Zogenix, Inc. started a Phase II clinical study of its drug candidate, fenfluramine, in subjects having epilepsy and Lennox Gastaut Syndrome. The purpose of the study was to evaluate the anti-epileptic effects of low dose fenfluramine in these patients. The trial was expected to be completed in March 2017, however, the study is still ongoing and recruiting participants. In June 2011, Eisai Inc. strated a Phase III study of drug candidate, rufinamide, to evaluate its safety, efficacy and pharmacokinetic activity in subjects of less than four years of age and having uncontrolled Lennox-Gastaut Syndrome. The trial was completed in November 2015.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/lennox-gastaut-syndrome-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of Lennox-Gastaut Syndrome therapeutics include, INSYS Therapeutics Inc., Eisai Inc., GW Research Ltd., Zogenix, Inc., Johnson & Johnson Pharmaceutical Research & Development, LLC, H. Lundbeck A/S, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Ortho-McNeil Pharmaceutical Ltd.

Hepatic Encephalopathy Therapeutics Pipeline Analysis 2017

Due to various risk factors the prevalence of hepatic encephalopathy has been increasing globally. The risk factors for the disease include the consumption of alcohol, drugs addiction for sedatives such as benzodiazepines; often used in treatment of anxiety disorders that can suppress the alcohol withdrawal, challenges in the correct diagnosis and other infections, such as jaundice and deficiency of liver enzymes. According to the Journal of Gastrointestinal & Digestive System, studies proves that in developed countries hepatic Encephalopathy affects the quality of life in around 70% of the patients suffering from liver cirrhosis. Hepatic encephalopathy is majorly diagnosed in the patients with liver cirrhosis. The therapeutic pipeline of hepatic Encephalopathy is expected to grow in the near future due to the involvement of several multinational pharmaceutical companies who have focused their research and development program on the production of a novel drugs for the treatment of hepatic encephalopathy.

Explore Report at: https://www.psmarketresearch.com/market-analysis/hepatic-encephalopathy-therapeutics-pipeline-analysis

Hepatic encephalopathy is a condition in which dysfunction of brain is observed in people with acute liver failure. The brain is the most important and sensitive organ in the body that relies on liver to perform various important biological functions. This condition can also occur due to kidney problems. According to the pathogenesis of hepatic encephalopathy, the liver has a detoxifying role in the body and has the capability of neutralizing numerous toxic chemicals which are absorbed from gastrointestinal tract. Most of the toxins going to the liver are pass through the portal venous system and these substances are effectively captured and detoxified by hepatocytes. With the progression of liver fibrosis and development of cirrhosis, the increased hepatic resistance forces the blood to bypass the liver by flowing through portosystemic shunts. This result in the pooling of various toxins into the systemic circulation which finally reaches the brain and other organs. The symptoms of the disease primarily associated with hepatic encephalopathy include Mood swings, reduced alertness, confusion, depression, disturbance in sleep pattern and anxiousness.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/hepatic-encephalopathy-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of hepatic encephalopathy include Kanna Life Sciences Inc., Horizon Pharma Plc, Rebiotix Inc, Ocera Therapeutics Inc., Umecrine Cognition AB, Spherium Biomed S.L., and COSMO Pharmaceuticals S.A.

Inflammatory Bowel Disorder Therapeutics Pipeline Analysis 2017

Globally, the prevalence of inflammatory bowel disorder has been increasing, mainly due to several risk factors such as high pollution due to rapid establishment of industries, smoking and habitual use of non-steroidal anti-inflammatory medicines. The inflammatory bowel disorder therapeutic pipeline is expected to grow in the future mainly due to the emergence of several novel drugs in the market, since various pharmaceutical and biotechnology companies have been focusing to develop drugs for the treatment of this disease. According to the Centers for Disease Control and Prevention (CDC), approximately 1 to 1.3 million population suffers from inflammatory bowel disorder, in the U.S.

Explore Report at: https://www.psmarketresearch.com/market-analysis/inflammatory-bowel-disorder-therapeutics-pipeline-analysis

Inflammatory bowel disorder is a condition in which patients feel chronic inflammation in all the parts of digestive tract. Inflammatory bowel disorder is very painful condition and may persist for a long time. Inflammatory bowel disorder primarily involves Crohn’s disease and ulcerative colitis, both these diseases are a type of inflammatory bowel syndrome. Ulcerative colitis mainly affects the large intestine (colon) whereas Crohn’s disease can affect any part of the digestive system, from the mouth to the anus. There are various symptoms which are associated with inflammatory bowel syndrome and some of them includes abdominal pain, weight loss, loss of appetite, fever, diarrhea, vomiting, anemia, and constipation.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/inflammatory-bowel-disorder-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of inflammatory bowel disorder therapeutics pipeline include Protagonist Therapeutics, Eli Lilly & Company, Arena Pharmaceuticals, Fast forward Pharmaceuticals, Jansen-Cilag Ltd, Redhill Biopharma Ltd, Kyowa Kirin Pharmaceutical Development, Inc.

Medical Image Management Market Size and Forecast to 2023

Medical Image Management Market

The global medical image management market is witnessing considerable growth due to technological advancements in diagnostic imaging modalities and image management solutions, increasing usage of imaging equipment, and increasing adoption of Vendor Neutral Archive (VNA). Moreover, increasing investment in the medical imaging, increasing adoption of imaging management system by small imaging centers and hospitals, and rapidly growing big data in healthcare are supporting the demand for medical image management systems. The increasing government initiatives to encourage electronic medical record adoption is further expected to boost the market. Based on product type, picture archiving and communication system (PACS) segment leads the global market in terms of size, due to technological advancements in PACS, increasing volume of imaging procedure and adoption of the PACS in new imaging segments such as mammography, endoscopy, oncology and ophthalmology. Hospitals have been the largest user of medical image management systems, owing to growing awareness about early diagnosis of diseases, increasing digitalization of patient’s data, rapid growth in adoption of EMR, and technological advancement in imaging modalities.

Explore Report at: https://www.psmarketresearch.com/market-analysis/medical-image-management-market

Medical image management is achieving medical images electronically with the assistance of image management systems. These systems gather, organize and control medical imaging data with various other patient information in healthcare systems. Application-independent clinical archives (AICA), PACS, VNA and are the key technologies used in image management systems.

The increasing female aging population is propelling the growth of the global Hysteroscope market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally, there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynaecological problems, such as abnormal uterine bleeding, fibroids, and polyps, as compared to adults, which is fuelling the demand of the global hysteroscope market. Aging in females leads to changes in hormones leading to irregular menses, which contributes to the demand for Geographically, North America has been the largest market for medical image management, owing to increasing geriatric population, and increasing prevalence of various diseases such as cancer and cardiovascular disease in the region. The U.S. contributed largest revenue to the North American as well as global medical image management market. The increasing adoption of technologically advanced imaging systems, and increasing awareness of the benefits of early diagnosis of diseases are the key growth driving factor for the U.S. medical image management market. Globally, the medical image management market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to the increasing geriatric population, large pool of patients, and increasing prevalence of various diseases in the region.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/medical-image-management-market/toc-sample

The key players operating in the global medical image management market are McKesson Corporation, General Electric Company, Fujifilm Holdings Corporation, Siemens AG, IBM Corporation, Koninklijke Philips N.V. and AGFA-Gevaert Group.

Sjögren’s Syndrome Therapeutics Pipeline Analysis, 2017 – Designation, Collaboration and Other Developments

Sjögren_s Syndrome Therapeutics Pipeline

The study analyzed that Sjögren’s syndrome pipeline comprises of approximately 42 drug candidates in different stages of development. Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia). It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

Browse Report Description at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis

The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren’s syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).

The research found that different companies have collaborated for the development of Sjögren’s syndrome.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample

Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.

Systemic Lupus Erythematosus Pipeline Analysis 2017

The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development. Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the immune system attacks its own tissues and can cause widespread inflammation and tissue damage in the affected organs. Some of the common symptoms of systemic lupus erythematosus include oral ulcers, sun sensitivity, heart problems, kidney problems, psychosis, lung problems, arthritis, seizures, fevers, skin rashes, fatigue, swelling and pain in the joints. Systemic lupus erythematosus is being treated using a combination approach as number of organs are involved. Therefore, various combination therapies are being used to improve quality of life of the patients. Also, combining novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Explore Report Description at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis

Seattle Genetics, Inc. is using antibody-drug conjugate (ADC) technology platform for the development of Brentuximab vedotin for the treatment of systemic lupus erythematosus. The technology platform employs a monoclonal antibody specific for a tumor-associated antigen, plus synthetic cytotoxic (cell-killing) agents connected by stable linker systems designed to securely bind the cytotoxic agent to the antibody and then release the agent within the targeted cell.

The research also found that various companies have collaborated for the development of systemic lupus erythematosus pipeline.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample

Some of the key players developing drugs for systemic lupus erythematosus include Anthera Pharmaceuticals, Inc., Genentech, Inc., Merck KGaA and others.

Pharmaceutical Membrane Technology Market Opportunities and Demand Forecast to 2023

Pharmaceutical Membrane Technology Market

Membrane technology is also widely used in improving water quality by removing particles, natural organic matter, pathogens (viruses and bacteria), emerging substances, and other dissolved matter from drinking water. Furthermore, membrane technology is used for the improvement of biological stability of drinking water in the distribution network. Water companies are legally forced to enhance the quality of drinking water in order to fulfill public health requirements. The enhancement is achieved by improving water quality and by operating water treatment processes more cost-efficiently with the help of membrane technology.

For more information visit: https://www.psmarketresearch.com/market-analysis/pharmaceutical-membrane-technology-market

Global pharmaceutical membrane technology market can be categorized on the basis of technology as ultrafiltration, reverse osmosis, microfiltration, chromatography and, nano filtration. Some of the major trends in the membrane technology market are product innovation and product portfolio expansion. The global membrane technology market is also going through large number of mergers, acquisitions and collaborations in recent years.

North America is the largest market for pharmaceutical membrane technology, owing to high concentration of pharmaceutical and biopharmaceutical manufacturing companies in the region. In Europe, many organizations, associations and societies are involved in development and implementation of membrane technology in pharmaceutical, biopharmaceutical and life sciences industries. However, Asia-Pacific is the fastest growing market for pharmaceutical membrane technology due to continuous development in pharmaceutical and biopharmaceutical industries. Additionally, increasing healthcare awareness, growing incidence of life style diseases, large population base and increasing government healthcare spending in developing countries of Asia-Pacific is driving the market for pharmaceutical membrane technology.

Request for Table of Content: https://www.psmarketresearch.com/market-analysis/Pharmaceutical-Membrane-Technology-Market/toc-sample

Some of the major competitors in global pharmaceutical membrane technology market are Amazon Filters Ltd., 3M Company, Pall Corporation, Advantec MFS Inc., Sartorius AG, GE Healthcare Life Sciences, Novasep, Merck Millipore (EMD Millipore), Koch Membrane Systems Inc., and TriSep Corporation.